Biogen (NASDAQ:BIIB) shares slid 12.9% in June, according to data provided by S&P Global Market Intelligence, as the company lost a patent ruling on its blockbuster multiple sclerosis (MS) drug.As for Vumerity, launched late last year, sales haven't yet picked up, even though the drug offers the same efficacy as Tecfidera but with fewer side effects.